Related Experiment Video
Updated: May 27, 2025
11:32
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
15.0K
The Complex Landscape of Updated Pneumococcal Conjugate Vaccines.
Deus Thindwa1, Eugene D Shapiro2,3, Daniel M Weinberger1
1Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit, Yale School of Public Health, New Haven, Connecticut, USA.
Open Forum Infectious Diseases
|February 19, 2025
Summary
Pneumococcal conjugate vaccines (PCVs) help prevent infections, but new vaccines are needed to address remaining disease burdens. Policy decisions must consider factors like serotype coverage, immune response, and cost for optimal use.
Area of Science:
- Infectious Diseases
- Vaccinology
- Public Health Policy
Background:
- Streptococcus pneumoniae (pneumococcus) causes significant global disease burden, particularly in vulnerable populations.
- Pneumococcal conjugate vaccines (PCVs) have reduced disease incidence but do not cover all disease-causing serotypes.
- A substantial burden of pneumococcal disease persists, necessitating the development and evaluation of new PCVs.
Purpose of the Study:
- To discuss key factors influencing policy decisions regarding the optimal use of existing and new pneumococcal conjugate vaccines (PCVs).
- To highlight considerations for selecting and implementing new PCVs to maximize public health impact.
- To emphasize the need for ongoing surveillance and data analysis in pneumococcal disease prevention strategies.
Main Methods:
- Review of current literature and data on pneumococcal disease epidemiology and vaccine effectiveness.
- Analysis of factors relevant to PCV policy, including serotype coverage, immune response, vaccine evasion, cost, and co-administration.
- Discussion of the role of surveillance data in informing vaccine policy and recommendations.
Main Results:
- New PCVs offer expanded serotype coverage to address the remaining disease burden.
- Policy decisions require careful consideration of vaccine characteristics, disease epidemiology, and economic factors.
- Optimal implementation strategies may involve simultaneous use of different PCVs in various age groups.
Conclusions:
- Informed policy decisions are crucial for maximizing the benefits of pneumococcal conjugate vaccines (PCVs).
- Robust surveillance and data analysis are essential for adapting vaccination strategies to evolving pneumococcal epidemiology.
- Continued research and monitoring are needed to guide the effective use of PCVs in preventing pneumococcal infections.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
1.8K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
1.8K
01:28Pneumonia IV: Management
287
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
287
01:30Pneumonia I: Introduction
201
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
201
02:50Conjugated Proteins
18.2K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.2K
01:30Pneumonia III: Complications and Assessment
146
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
146
01:51Vaccinations
43.8K
Overview
43.8K